Acute oxalate nephropathy associated with orlistat

Journal of Nephropathology

Volumn 5, Issue 2, 2016, Pages 79-83

  Humayun, Youshay ^a   Ball, Kenneth C ^a   Lewin, Jack R ^a   Lerant, Anna A ^a,b   Fülöp, Tibor ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Dialysis; Orlistat; Oxalate; Oxalate nephropathy; Proton pump inhibitor; Weight loss supplement

Indexed keywords

EID: 84963603741     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.15171/jnp.2016.14     Document Type: Article

References (23)

1. Nasr SH, D’Agati VD, Said SM, Stokes MB, Largoza MV, Radhakrishnan J, et al. Oxalate nephropathy complicating Roux-en-Y gastric bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol. 2008;3(6):1676-83. doi: 10.2215/cjn.02940608.
2. Mascio HM, Joya CA, Plasse RA, Baker TP, Flessner MF, Nee R. An unusual cause of acute kidney injury due to oxalate nephropathy in systemic scleroderma. Clin Nephrol. 2015;84(8):111-5. doi: 10.5414/CN108406.
3. Rankin A, Walsh S, Summers S, Owen M, Mansell M. Acute oxalate nephropathy causing late renal transplant dysfunction due to enteric hyperoxaluria. Am J Transplant. 2008;8(8):1755-8. doi: 10.1111/j.1600-6143.2008.02288.x.
4. Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis. 2007;49(1):153-7.
5. Karamadoukis L, Shivashankar G, Ludeman L, Williams A. An unusual complication of treatment with orlistat. Clin Nephrol. 2009;71(4):430-2. doi: 10.5414/CNP71430.
6. O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778-81. doi: 10.1016/j.amjmed.2005.02.007.
7. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J. 2008;179(4):319-26. doi: 10.1503/cmaj.071330.
8. Harvey JA, Zobitz MM, Pak CY. Calcium citrate: reduced propensity for the crystallization of calcium oxalate in urine resulting from induced hypercalciuria of calcium supplementation. J Clin Endocrin Metab. 1985;61(6):1223-5. doi: 10.1503/cmaj.071330.
9. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806-14. doi: 10.1503/cmaj.071330.
10. Chandra A, Biersmith M, Tolouian R. Obesity and kidney protection. J Nephropathol. 2014;3(3):91.
11. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100-7.
12. Sarica K, Akarsu E, Erturhan S, Yagci F, Aktaran S, Altay B. Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor. Obesity. 2008;16(7):1579-84. doi: 10.1038/oby.2008.244.
13. Chaudhari D, Crisostomo C, Ganote C, Youngberg G. Acute oxalate nephropathy associated with orlistat: a case report with a review of the literature. Case Reports Nephrol. 2013;2013: 124604. doi: 10.1155/2013/124604.
14. Coutinho AK, Glancey GR. Orlistat, an under-recognised cause of progressive renal impairment. Nephrol Dial Transplant. 2013;28(suppl 4):iv172-4.
15. Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171(7):703-4. doi: 10.1001/archinternmed.2011.103.
16. Karamadoukis L, Ludeman L, Williams AJ. Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis? Nephrol Dial Transplant. 2008;23(5):1778-79. doi: 10.1093/ndt/gfm945.
17. Tavares MB, Chagas de Almeida Mda C, Martins RT, de Sousa AC, Martinelli R, dos-Santos WL. Acute tubular necrosis and renal failure in patients with glomerular disease. Ren Fail. 2012;34(10):1252-7. doi: 10.3109/0886022X.2012.723582.
18. Fülöp T, Alemu B, Dossabhoy NR, et al. Safety and Efficacy of Percutaneous Renal Biopsy by Physicians-in-Training in an Academic Teaching Setting. South Med J. 2014;107(8):520-5. doi: 10.14423/SMJ.0000000000000148.
19. Hoffman GS, Schumacher HR, Paul H, Cherian V, Reed R, Ramsay AG, et al. Calcium oxalate microcrystalline-associated arthritis in end-stage renal disease. Ann Int Med. 1982;97(1):36-42.
20. Costello JF, Sadovnic MJ, Cottington EM. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol. 1991;1(12):1289-98.
21. Baxmann AC, Mendonça CD, Heilberg IP. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int. 2003;63(3):1066-71.
22. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A. 1996;93(8):3704-9. doi: 10.1073/pnas.93.8.3704.
23. Alhamad T, Blandon J, Meza AT, Bilbao JE, Hernandez GT. Acute kidney injury with oxalate deposition in a patient with a high anion gap metabolic acidosis and a normal osmolal gap. J Nephropathol. 2013;2(2):139. doi: 10.5812/nephropathol.10657.